E.coli-Proteus bacteriophage
Bacteriophages
Description
The preparation causes specific lysis of bacteria P. vulgaris, P. mirabilis, E. coli.
Presentation
Solution for oral, local and external administration, 20 ml or 100 ml vials. Eight 20 ml vials or one 100 ml vial in each cardboard package with a package insert.
Ingredients
The drug is a mixture of sterile filtrates of phage lysates of Proteusvulgaris, Proteusmirabilis and enteropathogenic Escherichiacoli of different serogroups, the most important in the etiology of inflammatory and enteric diseases.
Excipients:
Preservative - 8-hydroxyquinoline sulfate monohydrate - 0.0001 g/ml (estimated content);
or 8-hydroxyquinoline sulfate monohydrate - 0.0001 g/ml (equal to 8-hydroxyquinoline sulfate, estimated content).
Indications
Treatment and prevention of purulent inflammatory and enteric diseases, dysbacteriosis caused by bacteria Proteus and enterotoxigenic Escherichia coli in the complex therapy:
- diseases of the ear, nose, throat, respiratory tract and lungs - inflammation of the sinuses, middle ear, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy;
- surgical infections - festering wounds, burns, abscesses, pyogenic cellulitis, boils, carbuncles, hidradenitis, felon, perirectitis, mastitis, bursitis, osteomyelitis;
- urogenital infections - urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis;
- enteric infections - gastroenterocolitis, cholecystitis, intestinal dysbacteriosis;
- Generalized septic diseases;
- purulent inflammatory diseases of newborns - omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.;
- Other diseases caused by Escherichia coli and Proteus.
An important condition for the effective phage therapy is a preliminary determination of the phage sensitivity of the pathogen.
